A preliminary search of the Cochrane Database of Systematic Reviews, JBI Evidence Synthesis, PROSPERO, and MEDLINE found no current systematic or scoping reviews on GLP-1 peptide agonists and HCC risk and treatment management. This evidence concerns the gene GCG and hepatocellular carcinoma.